# NCT05265091 (NCT05265091)

> A Study of KL590586 in Patients With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05265091
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Advanced Solid Tumor
- Interventions: KL590586 Capsule
- Enrollment: 414
- Primary outcome: Phase I: Dose limiting toxicities (DLT)
- Primary outcome: Phase II: ORR

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05265091